With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly Asia Ventures.

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...